Compact, Dedicated Breast PET Scanner Being Developed

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 10
Volume 11
Issue 10

WASHINGTON-The imaging methods presently used to detect, diagnose, and stage breast tumors have significant flaws, as shown by the roughly 75% of breast biopsies that return normal results. These "completely unnecessary" procedures impose "huge costs" and "unnecessary trauma," said Craig S. Levin, PhD, assistant professor of radiology, University of California, San Diego, and the Department of Nuclear Medicine, San Diego VA Medical Center.

WASHINGTON—The imaging methods presently used to detect, diagnose, and stage breast tumors have significant flaws, as shown by the roughly 75% of breast biopsies that return normal results. These "completely unnecessary" procedures impose "huge costs" and "unnecessary trauma," said Craig S. Levin, PhD, assistant professor of radiology, University of California, San Diego, and the Department of Nuclear Medicine, San Diego VA Medical Center.

Although positron emission tomography (PET) imaging offers a potential alternative, existing PET systems have significant drawbacks as breast imaging devices, he said. Designed for whole-body coverage, they are large and entail "difficult geometry" in capturing the breast. Studies currently are expensive and result in "nonoptimal" breast images.

One potential solution could be a compact dedicated PET device using an improved sensor system in a "very compact" camera, he said at the Susan G. Komen Breast Cancer Foundation 5th Annual Conference on Innovations in Quality Care. The camera could be placed "right up against the breast," he said, and could also "move to other areas," such as the axilla. Dr. Levin’s team have built a laboratory at the San Diego VA Medical Center dedicated to this project. They currently are developing a "detector" for sensing and localizing positron energy.

Early results show that the new detector will produce spatial resolution five times better than existing PET scanners. Such high resolution suggests that the detector might eventually find currently undetected very small tumors.

Dr. Levin emphasized that "a lot of this is hypothetical" at present. He also stressed that the detector is not "meant to replace present technology," but rather to provide "an additional tool when present methods are inconclusive." 

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content